UNITED THERAPEUTICS Corp (UTHR) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-23

Key Insights

CEO Martine Rothblatt executed a significant net sale of 7,020 shares on 04/22/2026 through a pre-arranged 10b5-1 trading plan, selling at prices ranging from $572-$580 while exercising 9,500 options at $146.03, suggesting planned portfolio rebalancing rather than distress selling.
The 10b5-1 trading plan adopted on November 7, 2025 authorizes exercise and sale of up to 1,734,410 stock options (expiring March 2027) through December 31, 2026, indicating the CEO is systematically executing a substantial insider trading program over the next 8 months.
Rothblatt maintains substantial beneficial ownership of approximately 728,118 shares across direct holdings and family trusts, demonstrating continued significant economic alignment with the company despite the planned sales.
All transactions occurred on a single date (04/22/2026) with multiple trades executed at incrementally higher prices, consistent with a controlled systematic selling strategy rather than reactive market timing or loss of confidence.

Want the newest filings?

This analysis covers the filing from 2026-04-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-20

CEO Martine Rothblatt executed a significant net sale of 8,440 shares on 04/17/2026 through a pre-arranged 10b5-1 trading plan adopted in November 2025, while simultaneously exercising 9,500 stock options at $146.03, indicating planned liquidity management rather than loss of confidence.
Sales were executed across a narrow price range ($574.70-$592.30), suggesting disciplined execution throughout the trading day, with the largest single transaction being 2,088 shares at $589.32, reflecting methodical portfolio rebalancing.
Rothblatt maintains substantial beneficial ownership of 738,118 shares including direct holdings (40,513 shares) and significant indirect holdings through trusts (628,158 shares combined), demonstrating continued substantial alignment with shareholder interests despite the net sale activity.
The 10b5-1 plan authorizes up to 1,734,410 option exercises through March 2027 with a December 31, 2026 termination date, suggesting potential for additional significant transactions during this period if the plan remains active.

Filed: 2026-04-14

The reporting person, James Edgemond, exercised 10,000 stock options and subsequently sold 6,565 shares of United Therapeutics Corp (UTHR) common stock in multiple transactions on 2026-04-13, indicating ongoing insider selling activity.
The sale transactions were executed at prices ranging from $569.28 to $579.56 per share, suggesting the reporting person is monetizing a portion of their equity holdings.
The reporting person continues to hold 18,876 shares of United Therapeutics common stock following the reported transactions, indicating they maintain a significant ownership stake in the company.

Filed: 2026-04-14

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, executed a pre-arranged 10b5-1 trading plan on April 13, 2026, exercising 9,500 stock options and selling the resulting shares.
The sale of shares was executed in multiple tranches at prices ranging from $569.77 to $579.53, indicating a potential liquidity event for the CEO.
Rothblatt holds a significant amount of United Therapeutics stock, both directly and through various trust structures, suggesting a strong alignment with shareholder interests.

Filed: 2026-04-13

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, exercised 9,500 stock options and subsequently sold 8,500 shares of the company's common stock on April 10, 2026 under a pre-arranged 10b5-1 trading plan.
The transactions were executed at prices ranging from $566.44 to $573.01, with a weighted average sale price of around $568.97 per share.
Rothblatt continues to hold a significant stake in United Therapeutics, both directly and indirectly through various family trusts, suggesting ongoing commitment to the company's long-term success.

Filed: 2026-04-10

James Edgemond, the CFO and Treasurer of United Therapeutics Corporation, exercised 10,000 stock options and subsequently sold 8,210 shares of the company's common stock on April 9, 2026 pursuant to a Rule 10b5-1 trading plan.
The sale of shares was executed in multiple transactions at prices ranging from $574.18 to $582.30, indicating Edgemond's confidence in the company's current valuation.
The total number of shares beneficially owned by Edgemond decreased from 28,876 to 18,876 as a result of the reported transactions, suggesting he is diversifying his holdings.

Filed: 2026-04-10

The reporting person, Martine A. Rothblatt, who is the Chairperson and CEO of United Therapeutics Corporation, exercised 9,500 stock options and sold 7,652 shares of common stock on April 9, 2026 pursuant to a pre-arranged 10b5-1 trading plan.
The sale of shares was executed in multiple trades at weighted average prices ranging from $574.29 to $581.45, suggesting the reporting person was able to achieve favorable pricing for the transactions.
The reporting person maintains a significant direct and indirect beneficial ownership of United Therapeutics Corporation's common stock, with over 40,000 shares held directly and additional shares held in various family trusts, indicating continued commitment to the company.

Filed: 2026-04-09

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, exercised 9,500 stock options and sold 6,727 shares of the company's common stock on April 8, 2026 as part of a pre-arranged 10b5-1 trading plan.
The insider sales were executed at prices ranging from $564.97 to $585.48 per share, indicating Rothblatt's confidence in the company's current valuation.
Rothblatt continues to hold a substantial stake in United Therapeutics, with beneficial ownership of over 480,000 shares, indicating her long-term commitment to the company's success.

Filed: 2026-04-08

The reporting person, Martine A. Rothblatt, who is the Chairperson and CEO of United Therapeutics Corp, has exercised 9,500 stock options and sold 6,548 shares of common stock on April 7, 2026 pursuant to a pre-arranged 10b5-1 trading plan.
The reporting person still holds 93,000 stock options and 40,637 shares of common stock directly, as well as indirect beneficial ownership of 324,518 shares, 258,117 shares, 45,596 shares, and 10,962 shares through various trusts.
The reporting person's transactions were executed at a weighted average price range of $556.89 to $569.62 per share, indicating the stock is trading at a relatively high price point.

Filed: 2026-04-07

James Edgemond, the CFO and Treasurer of United Therapeutics, exercised 10,000 stock options and subsequently sold 6,826 shares in a series of transactions on April 6, 2026.
The transactions were made pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned and systematic approach to portfolio management.
The sale prices ranged from $552.78 to $566.01, suggesting that Edgemond may have been taking advantage of a favorable stock price to diversify his holdings.

Filed: 2026-04-07

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, exercised 9,500 stock options and subsequently sold 6,612 shares of common stock on April 6, 2026 as part of a pre-arranged 10b5-1 trading plan.
The total number of shares beneficially owned by Rothblatt, including direct and indirect holdings, decreased from 491,274 to 473,133 as a result of the transactions.
The transactions were executed at prices ranging from $552.37 to $566.00, suggesting the insider is taking advantage of the current stock price levels.

Filed: 2026-04-06

Insider James Edgemond, the CFO and Treasurer, exercised 10,000 stock options and subsequently sold 6,234 shares of United Therapeutics Corp (UTHR) on April 2, 2026 pursuant to a pre-arranged trading plan.
The sale transactions were executed at a range of prices from $551.68 to $571.65 per share, indicating Edgemond's confidence in the company's stock performance.
The total number of shares beneficially owned by Edgemond decreased from 28,876 to 18,876 after the reported transactions, representing a significant reduction in his direct ownership stake.

Filed: 2026-04-06

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, exercised 9,500 stock options and sold a total of 5,619 shares on April 2, 2026.
The sale of shares was conducted in a pre-arranged 10b5-1 trading plan, which suggests a planned and disciplined approach to managing insider transactions.
Rothblatt still holds a significant direct ownership position of 40,713 shares, as well as indirect ownership through various trusts, indicating continued alignment with shareholders.

Filed: 2026-03-25

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, exercised 9,500 stock options and subsequently sold 5,218 shares of the company's common stock through a pre-arranged 10b5-1 trading plan.
The insider selling activity represents a small portion of Rothblatt's overall beneficial ownership, which includes direct ownership, shares held in trusts, and shares held by her spouse.
The reported transactions were executed at prices ranging from $516.71 to $536.02, suggesting that Rothblatt may have timed the sales to take advantage of the stock's recent price appreciation.

Filed: 2026-03-24

Insider James Edgemond, the CFO and Treasurer, exercised 10,000 stock options and sold a total of 6,689 shares of United Therapeutics on March 23, 2026 pursuant to a Rule 10b5-1 trading plan.
The reported transactions were executed in multiple trades at prices ranging from $517.82 to $536.275, with Edgemond retaining 18,876 shares of the company's common stock following the reported transactions.
The sale of shares by the CFO and Treasurer could indicate a potential belief in the current valuation of the company's stock or a need to diversify personal holdings, though the transactions were made as part of a pre-arranged trading plan.

Filed: 2026-03-24

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold 5,660 shares of United Therapeutics common stock on March 23, 2026, continuing a pre-arranged 10b5-1 trading plan.
The sale of shares was executed in multiple transactions at prices ranging from $517.81 to $536.16, with the weighted average price reported for each trade.
Rothblatt continues to beneficially own a substantial number of United Therapeutics shares, including direct holdings of 40,513 shares and indirect holdings through trusts totaling 639,203 shares.

Filed: 2026-03-24

Judy D. Olian, a director of United Therapeutics Corp, has sold 200 shares of common stock at $530 per share pursuant to a pre-arranged 10b5-1 trading plan.
The transaction represents a small portion of Olian's overall beneficial ownership, which remains at 4,245 shares.
Insider selling can sometimes signal management's view on the company's near-term prospects, though a single transaction should not be over-interpreted in isolation.

Filed: 2026-01-20

The reporting person, Jan Malcolm, a director of United Therapeutics Corporation (UTHR), sold 50 shares of the company's common stock on January 16, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.
The sale price was $460.98 per share, and Malcolm now holds 320 shares of UTHR directly.
Insider selling, even under a Rule 10b5-1 plan, can be a signal of management's outlook on the company's prospects, though the overall significance depends on factors like the seller's total holdings and the percentage sold.

Filed: 2026-01-15

The EVP and General Counsel of United Therapeutics, Paul A. Mahon, exercised 8,300 stock options and sold a portion of the resulting shares on January 15, 2026 under a pre-arranged 10b5-1 trading plan.
The sale of shares was executed in multiple trades at weighted average prices ranging from $468.32 to $474.74, indicating Mahon sold a significant portion of his holdings.
The transactions reduced Mahon's direct beneficial ownership of United Therapeutics common stock from 45,081 shares to 36,781 shares, a decrease of over 18%.

Filed: 2026-01-13

The reporting person, Michael Benkowitz, who is the President and COO of United Therapeutics Corporation, exercised stock options and subsequently sold the resulting shares pursuant to a Rule 10b5-1 trading plan.
The reporting person holds the exercised stock options and resulting shares in two different trusts, one of which he and his spouse are co-trustees and have shared investment and voting power, and another in which he has sole investment and voting power.
The significant volume of shares sold, totaling 22,500, suggests the reporting person may have liquidated a substantial portion of his equity holdings in the company.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.